Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTZJC802)

• DOT Name: Cytochrome P450 2D6 (CYP2D6)
• Synonyms: EC 1.14.14.-; CYPIID6; Cholesterol 25-hydroxylase; Cytochrome P450-DB1; Debrisoquine 4-hydroxylase
• Gene Name: CYP2D6
• UniProt ID: CP2D6_HUMAN
• PDB ID: 2F9Q; 3QM4; 3TBG; 3TDA; 4WNT; 4WNU; 4WNV; 4WNW; 4XRY; 4XRZ; 5TFT; 5TFU; 6CSB; 6CSD
• EC Number: 1.14.14.-
• Pfam ID: PF00067
• Sequence:
  MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
  LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
  LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
  AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
  LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
  DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
  HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
  LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
  FAFLVSPSPYELCAVPR
• Function: A cytochrome P450 monooxygenase involved in the metabolism of fatty acids, steroids and retinoids. Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the epoxidation of double bonds of polyunsaturated fatty acids (PUFA). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 20-hydroxyeicosatetraenoic acid ethanolamide (20-HETE-EA) and 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling. Catalyzes the hydroxylation of carbon-hydrogen bonds. Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis. Catalyzes the oxidative transformations of all-trans retinol to all-trans retinal, a precursor for the active form all-trans-retinoic acid. Also involved in the oxidative metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
• KEGG Pathway:
  Metabolism of xenobiotics by cytochrome P450 (hsa00980)
  Drug metabolism - cytochrome P450 (hsa00982)
  Endocrine resistance (hsa01522)
  Serotonergic sy.pse (hsa04726)
• Reactome Pathway:
  Miscellaneous substrates (R-HSA-211958)
  Xenobiotics (R-HSA-211981)
  CYP2E1 reactions (R-HSA-211999)
  Biosynthesis of maresin-like SPMs (R-HSA-9027307)
  Aspirin ADME (R-HSA-9749641)
  Fatty acids (R-HSA-211935)
• BioCyc Pathway: MetaCyc:HS01997-MONOMER

Molecular Interaction Atlas (MIA) of This DOT

This DOT Affected the Regulation of Drug Effects of 28 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Hydrogen peroxide	DM1NG5W	Approved	Cytochrome P450 2D6 (CYP2D6) increases the abundance of Hydrogen peroxide.	[43]
Cyclophosphamide	DM4O2Z7	Approved	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Cyclophosphamide.	[45]
Dopamine	DMPGUCF	Approved	Cytochrome P450 2D6 (CYP2D6) increases the abundance of Dopamine.	[50]
Tofacitinib	DMBS370	Approved	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Tofacitinib.	[52]
Amodiaquine	DME4RA8	Approved	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Amodiaquine.	[53]
Imiquimod	DM1TMA3	Approved	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Imiquimod.	[60]
Primaquine	DMWQ16I	Approved	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Primaquine.	[62]
Paliperidone	DM7NPJS	Approved	Cytochrome P450 2D6 (CYP2D6) affects the abundance of Paliperidone.	[66]
Afimoxifene	DMFORDT	Phase 2	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Afimoxifene.	[77]
(Z)-endoxifen	DMGDOS2	Phase 2	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of (Z)-endoxifen.	[77]
Ym-758	DMU79X2	Phase 2	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Ym-758.	[80]
Fluvoxamine	DMQTJSX	Phase 2 Trial	Cytochrome P450 2D6 (CYP2D6) decreases the metabolism of Fluvoxamine.	[81]
PMID28870136-Compound-52	DMFDERP	Patented	Cytochrome P450 2D6 (CYP2D6) affects the metabolism of PMID28870136-Compound-52.	[82]
Eugenol	DM7US1H	Patented	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Eugenol.	[83]
Bisphenol A	DM2ZLD7	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Bisphenol A.	[85]
Phencyclidine	DMQBEYX	Investigative	Cytochrome P450 2D6 (CYP2D6) affects the metabolism of Phencyclidine.	[86]
2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE	DMNQL17	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of 2-AMINO-1-METHYL-6-PHENYLIMIDAZO[4,5-B]PYRIDINE.	[88]
Arachidonic acid	DMUOQZD	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Arachidonic acid.	[89]
BRN-3548355	DM4KXT0	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of BRN-3548355.	[90]
NAPQI	DM8F5LR	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the abundance of NAPQI.	[91]
1,4-Naphthoquinone	DMTCMH7	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the abundance of 1,4-Naphthoquinone.	[92]
Ellipticine	DMHPYSM	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Ellipticine.	[93]
aconitine	DMFOZ60	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of aconitine.	[94]
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	DMPWB8G	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.	[95]
Imipramine oxide	DMZKABS	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the abundance of Imipramine oxide.	[97]
LM-4108	DMWLMTD	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of LM-4108.	[98]
m-chlorophenylpiperazine	DMM1J2D	Investigative	Cytochrome P450 2D6 (CYP2D6) affects the metabolism of m-chlorophenylpiperazine.	[99]
Tyramine	DM4UXT1	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the metabolism of Tyramine.	[50]

This DOT Affected the Drug Response of 48 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Aspirin	DM672AH	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Aspirin.	[44]
Ifosfamide	DMCT3I8	Approved	Cytochrome P450 2D6 (CYP2D6) increases the response to substance of Ifosfamide.	[46]
Haloperidol	DM96SE0	Approved	Cytochrome P450 2D6 (CYP2D6) affects the response to substance of Haloperidol.	[47]
Phenytoin	DMNOKBV	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Phenytoin.	[48]
Sertraline	DM0FB1J	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Sertraline.	[48]
Docetaxel	DMDI269	Approved	Cytochrome P450 2D6 (CYP2D6) affects the response to substance of Docetaxel.	[49]
Clomipramine	DMINRKW	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Clomipramine.	[48]
Atenolol	DMNKG1Z	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Atenolol.	[48]
Flecainide	DMSQDLE	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Flecainide.	[48]
Dronedarone	DMA8FS5	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the response to substance of Dronedarone.	[58]
Perhexiline	DMINO7Z	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the response to substance of Perhexiline.	[59]
Trazodone	DMK1GBJ	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Trazodone.	[48]
Nortriptyline	DM4KDYJ	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the response to substance of Nortriptyline.	[14]
Doxepin	DMPI98T	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Doxepin.	[48]
Dextromethorphan	DMUDJZM	Approved	Cytochrome P450 2D6 (CYP2D6) increases the response to substance of Dextromethorphan.	[63]
Hydrochlorothiazide	DMUSZHD	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Hydrochlorothiazide.	[48]
Procainamide	DMNMXR8	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Hepatotoxicity ADR of Procainamide.	[48]
Disopyramide	DM5SYZP	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Disopyramide.	[48]
Labetalol	DMK8U72	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Labetalol.	[48]
Bisoprolol	DM3UZ95	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Bisoprolol.	[48]
Chlorpheniramine	DM5URA2	Approved	Cytochrome P450 2D6 (CYP2D6) increases the response to substance of Chlorpheniramine.	[68]
Diltiazem	DMAI7ZV	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Diltiazem.	[48]
Sotalol	DML60TN	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Sotalol.	[48]
Propafenone	DMPIBJK	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Propafenone.	[48]
Oxycodone	DMXLKHV	Approved	Cytochrome P450 2D6 (CYP2D6) affects the response to substance of Oxycodone.	[70]
Dofetilide	DMPN1TW	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Dofetilide.	[48]
Tocainide	DMYNMDP	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Tocainide.	[48]
Amitriptyline	DMK7F9S	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Arrhythmia ADR of Amitriptyline.	[48]
Acebutolol	DM0TI4U	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Acebutolol.	[48]
Alogliptin	DM8WI3R	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Hypoglycaemia ADR of Alogliptin.	[48]
Maprotiline	DMPWB7T	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Maprotiline.	[48]
Venlafaxine	DMR6QH0	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Nausea and vomiting symptoms ADR of Venlafaxine.	[71]
Donepezil	DMIYG7Z	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the response of Donepezil.	[72]
Oliceridine	DM6MDCF	Approved	Cytochrome P450 2D6 (CYP2D6) affects the response to substance of Oliceridine.	[73]
Trimipramine	DM1SC8M	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Trimipramine.	[48]
Betaxolol	DM6EUL5	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Betaxolol.	[48]
Mexiletine	DMCTE9R	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Drug toxicity ADR of Mexiletine.	[48]
Practolol	DMGLZ26	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Practolol.	[48]
Mianserin	DMVKA4O	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Mianserin.	[48]
Timolol	DM3NXRU	Approved	Cytochrome P450 2D6 (CYP2D6) affects the response to substance of Timolol.	[75]
Nadolol	DMW6GVL	Approved	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Nadolol.	[48]
Chlorpromazine	DMBGZI3	Phase 3 Trial	Cytochrome P450 2D6 (CYP2D6) decreases the response to substance of Chlorpromazine.	[76]
Verapamil	DMA7PEW	Phase 2/3 Trial	Cytochrome P450 2D6 (CYP2D6) increases the Poisoning and toxicity ADR of Verapamil.	[48]
Alprenolol	DMYJ8Z3	Withdrawn from market	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Alprenolol.	[48]
Amineptine	DMGVNJ7	Withdrawn from market	Cytochrome P450 2D6 (CYP2D6) increases the Hepatotoxicity ADR of Amineptine.	[48]
Manganese	DMKT129	Investigative	Cytochrome P450 2D6 (CYP2D6) decreases the response to substance of Manganese.	[87]
xamoterol	DMOVJP3	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of xamoterol.	[48]
Bupranolol	DMUT9IQ	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the Adverse drug reaction ADR of Bupranolol.	[48]

This DOT Affected the Biotransformations of 17 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Morphine	DMRMS0L	Approved	Cytochrome P450 2D6 (CYP2D6) affects the chemical synthesis of Morphine.	[51]
Carvedilol	DMHTEAO	Approved	Cytochrome P450 2D6 (CYP2D6) affects the glucuronidation of Carvedilol.	[54]
Citalopram	DM2G9AE	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the methylation of Citalopram.	[55]
Amphetamine	DMSZQAK	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the methylation of Amphetamine.	[56]
Lamotrigine	DM8SXYG	Approved	Cytochrome P450 2D6 (CYP2D6) increases the glutathionylation of Lamotrigine.	[57]
Risperidone	DMN6DXL	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the hydroxylation of Risperidone.	[61]
Desloratadine	DM56YN7	Approved	Cytochrome P450 2D6 (CYP2D6) affects the chemical synthesis of Desloratadine.	[64]
Domperidone	DMBDPY0	Approved	Cytochrome P450 2D6 (CYP2D6) increases the hydroxylation of Domperidone.	[65]
Almogran	DM7I64Z	Approved	Cytochrome P450 2D6 (CYP2D6) decreases the methylation of Almogran.	[67]
Buspirone	DMBS632	Approved	Cytochrome P450 2D6 (CYP2D6) increases the oxidation of Buspirone.	[69]
Mequitazine	DMAFBCY	Approved	Cytochrome P450 2D6 (CYP2D6) increases the hydroxylation of Mequitazine.	[74]
N-DESMETHYLCLOZAPINE	DMVIRN3	Phase 2	Cytochrome P450 2D6 (CYP2D6) increases the chemical synthesis of N-DESMETHYLCLOZAPINE.	[78]
Saracatinib	DMBLHGP	Phase 2	Cytochrome P450 2D6 (CYP2D6) increases the oxidation of Saracatinib.	[79]
Nimesulide	DMR1NMD	Terminated	Cytochrome P450 2D6 (CYP2D6) increases the glutathionylation of Nimesulide.	[84]
Bufuralol	DMJSC07	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the hydrolysis of Bufuralol.	[45]
Dimemorfan	DM2Q3CL	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the oxidation of Dimemorfan.	[96]
O-DESMETHYL TRAMADOL	DM8ZG2I	Investigative	Cytochrome P450 2D6 (CYP2D6) increases the chemical synthesis of O-DESMETHYL TRAMADOL.	[100]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Valproate	DMCFE9I	Approved	Valproate increases the methylation of Cytochrome P450 2D6 (CYP2D6).	[1]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the methylation of Cytochrome P450 2D6 (CYP2D6).	[29]

59 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Tretinoin	DM49DUI	Approved	Tretinoin decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[3]
Quercetin	DM3NC4M	Approved	Quercetin decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]
Triclosan	DMZUR4N	Approved	Triclosan increases the expression of Cytochrome P450 2D6 (CYP2D6).	[4]
Phenobarbital	DMXZOCG	Approved	Phenobarbital decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[5]
Niclosamide	DMJAGXQ	Approved	Niclosamide decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[3]
Cannabidiol	DM0659E	Approved	Cannabidiol decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[6]
Rosiglitazone	DMILWZR	Approved	Rosiglitazone decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[7]
Ethanol	DMDRQZU	Approved	Ethanol increases the expression of Cytochrome P450 2D6 (CYP2D6).	[8]
Paclitaxel	DMLB81S	Approved	Paclitaxel decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[5]
Obeticholic acid	DM3Q1SM	Approved	Obeticholic acid increases the expression of Cytochrome P450 2D6 (CYP2D6).	[9]
Rifampicin	DM5DSFZ	Approved	Rifampicin increases the expression of Cytochrome P450 2D6 (CYP2D6).	[10]
Capsaicin	DMGMF6V	Approved	Capsaicin decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[11]
Lindane	DMB8CNL	Approved	Lindane decreases the expression of Cytochrome P450 2D6 (CYP2D6).	[12]
Cholecalciferol	DMGU74E	Approved	Cholecalciferol decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]
Warfarin	DMJYCVW	Approved	Warfarin decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]
Cimetidine	DMH61ZB	Approved	Cimetidine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[5]
Hydroxychloroquine	DMSIVND	Approved	Hydroxychloroquine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[13]
Pentamidine	DMHZJCG	Approved	Pentamidine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[3]
Methoxsalen	DME8FZ9	Approved	Methoxsalen decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]
Quinidine	DMLPICK	Approved	Quinidine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[14]
Terbinafine	DMI6HUW	Approved	Terbinafine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[15]
Methadone	DMTW6IU	Approved	Methadone decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[16]
Ethambutol	DMR87LC	Approved	Ethambutol decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[17]
Sibutramine	DMFJTDI	Approved	Sibutramine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[18]
Buprenorphine	DMPRI8G	Approved	Buprenorphine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[19]
MELARSOPROL	DMGUZ0W	Approved	MELARSOPROL decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[3]
Yn-968D1	DMMP3Y2	Approved	Yn-968D1 decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[20]
Cinacalcet	DMCX0K3	Approved	Cinacalcet decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[21]
Proguanil	DMBL79I	Approved	Proguanil decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[3]
Oxatomide	DM1F42Z	Approved	Oxatomide decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[22]
Ajmalicine	DMPOD47	Approved	Ajmalicine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[23]
Benidipine	DMWNP6B	Phase 4	Benidipine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[24]
Barnidipine	DMJSDBE	Phase 4	Barnidipine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[24]
Resveratrol	DM3RWXL	Phase 3	Resveratrol decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]
Curcumin	DMQPH29	Phase 3	Curcumin decreases the expression of Cytochrome P450 2D6 (CYP2D6).	[25]
Chloroquine	DMSI5CB	Phase 3 Trial	Chloroquine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[26]
Manidipine	DMJPGUA	Phase 3	Manidipine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[24]
MLN8237	DMO8PT9	Phase 3	MLN8237 affects the activity of Cytochrome P450 2D6 (CYP2D6).	[27]
Amiodarone	DMUTEX3	Phase 2/3 Trial	Amiodarone increases the expression of Cytochrome P450 2D6 (CYP2D6).	[28]
Norbuprenorphine	DM2ILSJ	Phase 1	Norbuprenorphine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[19]
EMODIN	DMAEDQG	Terminated	EMODIN decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[30]
Butanoic acid	DMTAJP7	Investigative	Butanoic acid increases the expression of Cytochrome P450 2D6 (CYP2D6).	[31]
Chlorpyrifos	DMKPUI6	Investigative	Chlorpyrifos increases the expression of Cytochrome P450 2D6 (CYP2D6).	[32]
Daidzein	DMRFTJX	Investigative	Daidzein decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]
Myricetin	DMTV4L0	Investigative	Myricetin decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[33]
LICOAGROCHACONE A	DMWY0TN	Investigative	LICOAGROCHACONE A affects the activity of Cytochrome P450 2D6 (CYP2D6).	[34]
MANGIFERIN	DMWAF5Z	Investigative	MANGIFERIN decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[35]
Isoarnebin 4	DM0B7NO	Investigative	Isoarnebin 4 decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[36]
Formononetin	DM7WFZ8	Investigative	Formononetin decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[37]
RHEIN	DMS6IJ0	Investigative	RHEIN decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[30]
(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE	DMTPQ84	Investigative	(11-BETA)-11,21-DIHYDROXY-PREGN-4-ENE-3,20-DIONE increases the expression of Cytochrome P450 2D6 (CYP2D6).	[38]
Cinnamic acid	DM340FH	Investigative	Cinnamic acid decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[39]
2-(5-fluoro-1H-indol-3-yl)ethanamine	DMHW5FT	Investigative	2-(5-fluoro-1H-indol-3-yl)ethanamine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[40]
1H-Indole-2,3-dione	DMOZ91H	Investigative	1H-Indole-2,3-dione increases the expression of Cytochrome P450 2D6 (CYP2D6).	[41]
1H-1,2,3-benzotriazol-1-amine	DM9KAI5	Investigative	1H-1,2,3-benzotriazol-1-amine decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[42]
Maackiain	DMDHGM2	Investigative	Maackiain decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[33]
5-MEO-DMT	DMG0EL7	Investigative	5-MEO-DMT decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[40]
BZ3	DMN5X17	Investigative	BZ3 decreases the activity of Cytochrome P450 2D6 (CYP2D6).	[2]

References

• [1] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [2] Functional expression and comparative characterization of nine murine cytochromes P450 by fluorescent inhibition screening. Drug Metab Dispos. 2008 Jul;36(7):1322-31.
• [3] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [4] Triclosan treatment decreased the antitumor effect of sorafenib on hepatocellular carcinoma cells. Onco Targets Ther. 2018 May 18;11:2945-2954.
• [5] Size-dependent effects of nanoparticles on the activity of cytochrome P450 isoenzymes. Toxicol Appl Pharmacol. 2010 Feb 1;242(3):326-32.
• [6] Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
• [7] Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
• [8] beta-Naphtoflavone and ethanol induce cytochrome P450 and protect towards MPP+ toxicity in human neuroblastoma SH-SY5Y cells. Int J Mol Sci. 2018 Oct 28;19(11).
• [9] Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
• [10] Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol. 2009 Mar 1;77(5):897-909.
• [11] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [12] Xenobiotic-metabolizing cytochromes p450 in human white adipose tissue: expression and induction. Drug Metab Dispos. 2010 Apr;38(4):679-86.
• [13] Somer M, Kallio J, Pesonen U, Pyykko K, Huupponen R, Scheinin M "Influence of hydroxychloroquine on the bioavailability of oral metoprolol." Br J Clin Pharmacol 49 (2000): 549-54. [PMID: 10848718]
• [14] Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
• [15] A metoprolol-terbinafine combination induced bradycardia. Eur J Drug Metab Pharmacokinet. 2015 Sep;40(3):295-9.
• [16] Expression, purification, and characterization of mouse CYP2d22. Drug Metab Dispos. 2006 Jul;34(7):1167-74.
• [17] Inhibition of cytochrome P450 by ethambutol in human liver microsomes. Toxicol Lett. 2014 Aug 17;229(1):33-40.
• [18] Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes. Chem Biol Interact. 2013 Sep 5;205(1):11-9.
• [19] Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.
• [20] Evaluation of the inhibition effects of apatinib on human and rat cytochrome P450. Toxicol Lett. 2018 Nov;297:1-7.
• [21] Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
• [22] Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
• [23] Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. Biol Pharm Bull. 2005 Jun;28(6):1021-4.
• [24] Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
• [25] Dimethoxycurcumin reduces proliferation and induces apoptosis in renal tumor cells more efficiently than demethoxycurcumin and curcumin. Chem Biol Interact. 2021 Apr 1;338:109410. doi: 10.1016/j.cbi.2021.109410. Epub 2021 Feb 12.
• [26] In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos. 2003 Jun;31(6):748-54.
• [27] Alisertib shows negligible potential for perpetrating pharmacokinetic drug-drug interactions on ABCB1, ABCG2 and cytochromes P450, but acts as dual-activity resistance modulator through the inhibition of ABCC1 transporter. Toxicol Appl Pharmacol. 2022 Jan 1;434:115823. doi: 10.1016/j.taap.2021.115823. Epub 2021 Dec 9.
• [28] Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. PLoS One. 2009 Sep 23;4(9):e7155.
• [29] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [30] Anthraquinones inhibit cytochromes P450 enzyme activity in silico and in vitro. J Appl Toxicol. 2021 Sep;41(9):1438-1445. doi: 10.1002/jat.4134. Epub 2021 Jan 12.
• [31] Butyrate interacts with benzo[a]pyrene to alter expression and activities of xenobiotic metabolizing enzymes involved in metabolism of carcinogens within colon epithelial cell models. Toxicology. 2019 Jan 15;412:1-11.
• [32] Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
• [33] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [34] Inhibition of human cytochrome P450 enzymes by licochalcone A, a naturally occurring constituent of licorice. Toxicol In Vitro. 2015 Oct;29(7):1569-76.
• [35] Mangifera indica Lextract and mangiferin modulate cytochrome P450 and UDP-glucuronosyltransferase enzymes in primary cultures of human hepatocytes. Phytother Res. 2013 May;27(5):745-52.
• [36] Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay. Toxicol Lett. 2017 Nov 5;281:74-83.
• [37] In vivo prediction of CYP-mediated metabolic interaction potential of formononetin and biochanin A using in vitro human and rat CYP450 inhibition data. Toxicol Lett. 2015 Nov 19;239(1):1-8.
• [38] Prenatal ethanol exposure induces dynamic changes of expression and activity of hepatic cytochrome P450 isoforms in male rat offspring. Reprod Toxicol. 2022 Apr;109:101-108. doi: 10.1016/j.reprotox.2022.03.002. Epub 2022 Mar 14.
• [39] Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity. J Mol Endocrinol. 2004 Apr;32(2):425-36.
• [40] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [41] Comparison of gene expression patterns between 2,3,7,8-tetrachlorodibenzo-p-dioxin and a natural arylhydrocarbon receptor ligand, indirubin. Toxicol Sci. 2004 Jul;80(1):161-9.
• [42] HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme. Br J Pharmacol. 2001 Jun;133(3):325-9. doi: 10.1038/sj.bjp.0704101.
• [43] Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
• [44] CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics. 1998 Dec;8(6):529-41. doi: 10.1097/00008571-199812000-00010.
• [45] Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicol In Vitro. 2001 Jun;15(3):245-56.
• [46] Advantages of human hepatocyte-derived transformants expressing a series of human cytochrome p450 isoforms for genotoxicity examination. Toxicol Sci. 2010 Aug;116(2):488-97. doi: 10.1093/toxsci/kfq154. Epub 2010 May 27.
• [47] Haloperidol half-life after chronic dosing. J Clin Psychopharmacol. 2004 Dec;24(6):656-60. doi: 10.1097/01.jcp.0000145340.53417.ca.
• [48] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
• [49] Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
• [50] Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
• [51] Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004 Dec 30;351(27):2827-31. doi: 10.1056/NEJMoa041888.
• [52] Tofacitinib Is a Mechanism-Based Inactivator of Cytochrome P450 3A4. Chem Res Toxicol. 2019 Sep 16;32(9):1791-1800. doi: 10.1021/acs.chemrestox.9b00141. Epub 2019 Aug 26.
• [53] Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: possible implications for susceptibility to amodiaquine-induced liver toxicity. Toxicol Lett. 2017 Jun 5;275:83-91.
• [54] Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol. J Pharm Pharm Sci. 2006;9(1):101-12.
• [55] Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics. 1997 Feb;7(1):1-10.
• [56] Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett. 2018 Mar 15;285:1-8. doi: 10.1016/j.toxlet.2017.12.017. Epub 2017 Dec 23.
• [57] Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. Chem Res Toxicol. 2010 Jan;23(1):159-70. doi: 10.1021/tx9003243.
• [58] The role of hepatic cytochrome P450s in the cytotoxicity of dronedarone. Arch Toxicol. 2018 Jun;92(6):1969-1981. doi: 10.1007/s00204-018-2196-x. Epub 2018 Apr 3.
• [59] Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury. Arch Toxicol. 2018 Jan;92(1):383-399. doi: 10.1007/s00204-017-2036-4. Epub 2017 Jul 31.
• [60] The Toll-like receptor agonist imiquimod is metabolized by aryl hydrocarbon receptor-regulated cytochrome P450 enzymes in human keratinocytes and mouse liver. Arch Toxicol. 2019 Jul;93(7):1917-1926.
• [61] Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005 Aug;255(4):261-8. doi: 10.1007/s00406-004-0556-4. Epub 2004 Nov 29.
• [62] Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol. 2009 Nov 15;241(1):14-22. doi: 10.1016/j.taap.2009.07.012. Epub 2009 Jul 17.
• [63] Myoclonus after dextromethorphan administration in peritoneal dialysis. Ann Pharmacother. 2011 Jan;45(1):e1. doi: 10.1345/aph.1P301. Epub 2010 Dec 14.
• [64] Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects. Drug Metab Dispos. 2005 Sep;33(9):1283-7. doi: 10.1124/dmd.105.005025. Epub 2005 Jun 2.
• [65] Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol. 2004 Sep;58(3):277-87.
• [66] Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
• [67] Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
• [68] Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol. 2006 Dec;62(12):995-1001. doi: 10.1007/s00228-006-0210-3. Epub 2006 Nov 7.
• [69] Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
• [70] Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol. 2010 Jun;160(4):919-30. doi: 10.1111/j.1476-5381.2010.00709.x.
• [71] CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther. 2006 Oct;31(5):493-502.
• [72] Replication study to confirm the role of CYP2D6 polymorphism rs1080985 on donepezil efficacy in Alzheimer's disease patients. J Alzheimers Dis. 2012;30(4):745-9. doi: 10.3233/JAD-2012-112123.
• [73] First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers. J Clin Pharmacol. 2014 Mar;54(3):351-7.
• [74] Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
• [75] Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther. 2009 Apr;25(2):163-71. doi: 10.1089/jop.2008.0028.
• [76] Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem Biol Interact. 2016 Aug 5;255:63-73. doi: 10.1016/j.cbi.2015.10.009. Epub 2015 Oct 22.
• [77] The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Arch Toxicol. 2018 Mar;92(3):1099-1112.
• [78] Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos. 2008 Dec;36(12):2547-55. doi: 10.1124/dmd.108.023671. Epub 2008 Sep 22.
• [79] Cytochrome P450 Mediated Bioactivation of Saracatinib. Chem Res Toxicol. 2016 Nov 21;29(11):1835-1842. doi: 10.1021/acs.chemrestox.6b00242. Epub 2016 Nov 3.
• [80] Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism. Eur J Drug Metab Pharmacokinet. 2008 Oct-Dec;33(4):211-23. doi: 10.1007/BF03190875.
• [81] Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34.
• [82] Comparison of various urine collection intervals for caffeine and dextromethorphan phenotyping in children. J Clin Pharmacol. 2004 Jul;44(7):708-14. doi: 10.1177/0091270004266624.
• [83] Copper-mediated oxidative DNA damage induced by eugenol: possible involvement of O-demethylation. Mutat Res. 2004 Dec 31;565(1):35-44. doi: 10.1016/j.mrgentox.2004.08.009.
• [84] Chemical and Enzymatic Transformations of Nimesulide to GSH Conjugates through Reductive and Oxidative Mechanisms. Chem Res Toxicol. 2015 Dec 21;28(12):2267-77. doi: 10.1021/acs.chemrestox.5b00290. Epub 2015 Nov 12.
• [85] Ipso substitution of bisphenol A catalyzed by microsomal cytochrome P450 and enhancement of estrogenic activity. Toxicol Lett. 2011 May 30;203(1):92-5. doi: 10.1016/j.toxlet.2011.03.010. Epub 2011 Mar 23.
• [86] Mechanism of inactivation of human cytochrome P450 2B6 by phencyclidine. Drug Metab Dispos. 2006 Sep;34(9):1523-9. doi: 10.1124/dmd.106.010579. Epub 2006 Jun 16.
• [87] Polymorphism of metabolic genes and susceptibility to occupational chronic manganism. Biomarkers. 2002 Jul-Aug;7(4):337-46. doi: 10.1080/13547500210146740.
• [88] A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Chem Res Toxicol. 2007 Mar;20(3):531-42. doi: 10.1021/tx600320w. Epub 2007 Feb 6.
• [89] Mediation of arachidonic acid metabolite(s) produced by endothelial cytochrome P-450 3A4 in monkey arterial relaxation. Hypertens Res. 2003 Mar;26(3):237-43. doi: 10.1291/hypres.26.237.
• [90] A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis. 1991 Jul;12(7):1197-201. doi: 10.1093/carcin/12.7.1197.
• [91] Acetaminophen reactive intermediates target hepatic thioredoxin reductase. Chem Res Toxicol. 2014 May 19;27(5):882-94. doi: 10.1021/tx5000443. Epub 2014 Apr 4.
• [92] In vitro metabolism of naphthalene by human liver microsomal cytochrome P450 enzymes. Drug Metab Dispos. 2006 Jan;34(1):176-83. doi: 10.1124/dmd.105.005785. Epub 2005 Oct 21.
• [93] Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5. Toxicology. 2012 Dec 16;302(2-3):233-41. doi: 10.1016/j.tox.2012.08.004. Epub 2012 Aug 16.
• [94] Involvement of CYP3A4/5 and CYP2D6 in the metabolism of aconitine using human liver microsomes and recombinant CYP450 enzymes. Toxicol Lett. 2011 Apr 10;202(1):47-54. doi: 10.1016/j.toxlet.2011.01.019. Epub 2011 Jan 28.
• [95] Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
• [96] The oxidative metabolism of dimemorfan by human cytochrome P450 enzymes. J Pharm Sci. 2010 Feb;99(2):1063-77.
• [97] What is the contribution of human FMO3 in the N-oxygenation of selected therapeutic drugs and drugs of abuse?. Toxicol Lett. 2016 Sep 6;258:55-70. doi: 10.1016/j.toxlet.2016.06.013. Epub 2016 Jun 15.
• [98] Studies on the metabolism of the novel, selective cyclooxygenase-2 inhibitor indomethacin phenethylamide in rat, mouse, and human liver microsomes: identification of active metabolites. Drug Metab Dispos. 2004 Jan;32(1):113-22.
• [99] Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug Metab Dispos. 2008 May;36(5):841-50.
• [100] Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol. 2008 Feb;28(1):78-83. doi: 10.1097/JCP.0b013e318160f827.